Mental Health “Mental health is currently a major problem in China, and will become an ever greater problem unless effective interventions are put in place.” Mental Health has Long Been a Serious Problem in China The most populous nation in the world is said by some to be “in the…
Pricing Generic drugs foster competition in the pharmaceutical market. Chester “Chip” Davis, Jr. of the Association for Accessible Medicines (AAM) reveals the data behind generic competition and elaborates on opportunities for further savings. The American public is clamoring for systemic changes to address skyrocketing drug prices. Specialty drugs—a growing category…
Japan Japan’s Opportunity to Establish a Blueprint for the World: Janssen Japan’s Chris Hourigan makes the case for increased investment in, and access to, innovative medicines as a key solution to countering the costs associated with an ageing population. Earlier this year, Emperor Naruhito ascended the Chrysanthemum Throne, and Japan…
Turkey Şükran Tümay, a senior partner at executive search and assessment firm Stanton Chase in Turkey, highlights the evolving profiles she looks for when hiring country managers for healthcare and the life sciences companies in the dynamic Turkish market. What are the qualities you look for in a Country Manager?…
Opinion Rare diseases and cell and gene therapy executive recruitment specialist Steve Smith outlines six key strategies for attracting and retaining talent in these rapidly emerging fields. In a young industry experiencing rapid growth, talent demand far outweighs supply Cell & Gene Therapy; “It’s no longer something people read about…
Opinion Frost & Sullivan’s Senior Research Analyst, Aarti Chitale looks at the sizeable impact that precision medicine, especially regenerative medicine, is already having on the global therapeutic landscape, and how the Asia-Pacific region is positioning itself at the forefront of this trend. Providing the right treatment/ right drug at the…
Opinion Veeva Systems Europe’s Paul Attridge highlights how a switch to a continuous model for regulatory operations could allow biopharmaceutical companies to submit high-quality regulatory submissions for their products faster than ever before. Like continuous manufacturing, which is widely employed in other industries and is starting to show signs of…
USA PwC’s Kelly Barnes examines how the US pharmaceutical sector is having to rethink its relationship with consumers, experimenting with new and innovative pricing models, and adopting a more holistic view of the patients using their medicines. American consumers want more than just lower prices from pharmaceutical companies US Consumers…
Vaccines MSD’s Cyril Schiever outlines why vaccine hesitancy is such a threat to global health, the misinformation around vaccines being spread online, and how multi-stakeholder collaboration can help counter this emerging problem. The World Health Organization (WHO) recently identified vaccine hesitancy as one of the top 10 global health threats…
Brazil Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves and their organizations. What are the qualities you look for in a Country Manager? Capable leaders are those who…
USA Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry. Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the…
Opinion Ulrich Neumann of Certara outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make on the global biopharma industry. While the collection of real-world data is not new, real-world evidence is poised to have a profound impact on the biopharma industry…
See our Cookie Privacy Policy Here